Pharming N.V.(US:PHAR) Globenewswire·2026-03-12 06:00Core Insights - Pharming Group N.V. reported a strong financial performance for 2025, with total revenues increasing by 27% to US$376.1 million, driven by growth in RUCONEST® and Joenja® [2][7][35] - The company achieved an operating profit of US$25.8 million in 2025, a significant improvement from a loss of US$8.6 million in 2024 [4][40] - Pharming anticipates total revenues for 2026 to be between US$405 million and US$425 million, representing growth of 8% to 13% [4][56] Financial Performance - Total revenues for Q4 2025 increased by 15% to US$106.5 million compared to Q4 2024 [29] - RUCONEST® revenues for the full year 2025 reached US$317.9 million, a 26% increase year-over-year, while Joenja® revenues increased by 29% to US$58.2 million [8][36] - The company reported a net profit of US$2.5 million for 2025, compared to a net loss of US$11.8 million in 2024 [43] Product Performance - RUCONEST® continues to be a key treatment option for patients with HAE, with a 9% revenue increase in Q4 2025 [8][9] - Joenja® saw a 53% revenue increase in Q4 2025, driven by a significant rise in patients on paid therapy in the U.S. [10][11] - The U.S. market accounted for 86% of Pharming's total revenues in 2025, highlighting the importance of this market for the company's growth [11] Pipeline and Future Outlook - Pharming's pipeline includes key upcoming milestones, such as Phase II readouts for leniolisib in broader primary immunodeficiencies expected in the second half of 2026 [6][21] - The company is on track to complete enrollment in the pivotal FALCON study for napazimone (KL1333) in 2026, with data readout anticipated in late 2027 [6][24] - Pharming aims to enhance capital allocation to drive growth and is focused on potential acquisitions and in-licensing opportunities in rare diseases [56]